Cardiovascular Risk Assessment and Management Making a Difference
|
|
- Eric Francis
- 6 years ago
- Views:
Transcription
1 Cardiovascular Risk Assessment and Management Making a Difference Norman Sharpe March 2014
2
3 Numbers and age-standardised mortality rates from all causes, by sex, Death rates halved Life expectancy increased
4 Numbers and age-standardised mortality rates from ischaemic heart disease, by sex, Heart disease death rates reduced by more than two-thirds since 1968
5 Age-standardised mortality rates for the five major causes of mortality, Cancer and heart disease crossover late 1980s
6
7
8
9 Specific conditions contributing > 1% of total DALYs Males 2006
10 Specific conditions contributing > 1% of total DALYs Females 2006
11 Attributable burden (% of DALYs) for selected risk factors, 2006
12 Projections in health loss attributable to tobacco and high BMI, total population, 2006 to 2016 Obesity exceeds tobacco for health loss beyond 2015
13 Leading specific causes of absolute inequality between Māori and non-māori, 2006
14 Primary Care The Keystone to Heart Health Improvement
15 Why bother about CVD in primary care? In a population of 10,000 primary care patients, every year there are about: 10 coronary & stroke deaths 1 diabetic death 1 breast cancer death 1 prostate cancer death 1 suicide every year 1 road traffic death (1 cervical cancer death every 5 years)
16 EVIDENCE-BASED BEST PRACTICE GUIDELINE Cardiovascular Risk Assessment and Management Guideline December 2003
17 CV Risk Guideline 2003 What was new --- Integrated previous advice on smoking, BP, lipids and diabetes into one assessment Required bloods (lipids and fasting glucose) Recommended screening of specific age groups Recommended all treatment decisions be based on absolute cardiovascular risk - CHD and stroke risk combined Recommended intervention for individuals with CV risk above 15% 5 year level as practical and cost effective
18 Assessment of absolute CV risk What to measure and record Age and sex Ethnicity Smoking history Family history Lipid profile and fasting glucose Average of two sitting BPs BMI and waist circumference Assessment of absolute risk is the starting point for discussion
19 What does a Risk Assessment Involve? Weight Blood Pressure Smoking Diabetes Gender Family History Age Cholesterol Levels Ethnicity
20 20
21 APCSC: blood pressure, cholesterol and body mass index and the risk of coronary heart disease Blood pressure Cholesterol Body mass index Hypertension Hypercholesterolaemia 1.0 Obesity Systolic blood pressure (mmhg) Total cholesterol (mmol/l) Body mass index (kg/m 2 ) 0.5
22 Hazard ratio & 95% CI APCSC: glucose and the risks of stroke, CHD, CV death ,257 participants and 1.2M person years of follow up Total stroke 4.0 Total ischaemic heart disease 4.0 Cardiovascular death Diabetes Care 27: 2836, 2004 Usual fasting glucose (mmol/l) 1mmol/l reduction in UFG relates to 23% reduced risk IHD
23 5 year CVD risk (percent) Absolute risk of CVD over 5 years by systolic BP + other risk factors Reference category is a 50 year old nondiabetic, non-smoker female with total cholesterol 4 0 mmol/l and HDL 1 6 mmol/l. 44% Risks are given for SBP levels of 110, 120, 130, 140, 150, 160, 170, and 180 mm Hg 33% 24% 18% 12% <1% 3% 6% Reference TC Smoker HDL Male Diabetes 60 years 7mmol/L 1 mmol/l Jackson R. Lat 2005;365:434
24 Clinically High Risk Adjusted CVD Risk Clinical CVD or High risk diabetes Some genetic lipid disorders Treatment Intensity Consider specialist referral Urgent + intense multifactor treatment Drug intervention directed at all risk factors Drug interventions General advice Specific advice Lifestyle Intensive individual advice interventions CVD Risk goal Reduce risk Reduce 5-year CVD risk to < 15%
25
26
27
28
29 So, what is shared decision making? Informed (benefits and harms) patient preference Health professional expertise Discussion Treatment and/or behaviour change goal The patient shares: Impact of risk/condition on their life. Personal attitude to the risk Values Preference Health beliefs The health professional shares: Knowledge Experience Treatment options and possible evidence based outcomes Coulter, A., Collins, A. (2011). Making shared decision-making a reality: No decision about me, without me. The King s Fund Health foundation you tube
30
31
32
33 Making it happen: practice change Leadership Champion Change management Team approach Quality improvement Data collection and clean up Achievable goals and targets Continual practice improvement Patient Access Improved patient outcomes Meeting health target Happy staff Innovation Person and family centred care Community outreach Self Management- organisational and individual
34
35
36
Professor Norman Sharpe. Heart Foundation West Coast
Professor Norman Sharpe Heart Foundation West Coast Primary Care the Keystone to Heart Health Improvement Norman Sharpe June 2013 The heart health continuum and the keystone position The culprit disease
More informationKey causes of preventable deaths in New Zealand In a population of 10,000 New Zealanders, every year there will be about:
Preventive care - Chronic Disease Management in primary care: a population perspective Rod Jackson University of Auckland New Zealand (22/11/8) Key causes of preventable deaths in New Zealand In a population
More informationHEALTH TARGETS IN PRIMARY CARE
HEALTH TARGETS IN PRIMARY CARE MORE HEART AND DIABETES CHECKS BETTER HELP FOR SMOKERS TO QUIT Better Help for Smokers to Quit 90% of enrolled patients who smoke and are seen by General Practice, will be
More informationCurrent Issues in Cardiovascular Risk Management. Les Toop Norman Sharpe June 2014
Current Issues in Cardiovascular Risk Management Les Toop Norman Sharpe June 2014 Risk assessment is just the beginning of a conversation Les Toop Department of General Practice, University of Otago, Christchurch
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationDepok-Indonesia STEPS Survey 2003
The STEPS survey of chronic disease risk factors in Indonesia/Depok was carried out from February 2003 to March 2003. Indonesia/Depok carried out Step 1, Step 2 and Step 3. Socio demographic and behavioural
More informationVascular Diseases. Overview: Selected Slides
Vascular Diseases Overview: Selected Slides Total deaths and change in vascular death rates
More informationBEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS
BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS Neil R Poulter ICCH, Imperial College London BHIVA: October 10th, 2008 Background CVD is the biggest single killer in the world CVD rates are increasing High
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationCardiovascular Disease Prevention: Current Knowledge, Future Directions
Cardiovascular Disease Prevention: Current Knowledge, Future Directions Daniel Levy, MD Director, Framingham Heart Study Professor of Medicine, Boston University School of Medicine Editor-in-Chief, Journal
More informationwell-targeted primary prevention of cardiovascular disease: an underused high-value intervention?
well-targeted primary prevention of cardiovascular disease: an underused high-value intervention? Rod Jackson University of Auckland, New Zealand October 2015 Lancet 1999; 353: 1547-57 Findings: Contribution
More information2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE
2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE Massimo F Piepoli, MD, PhD, FESC, Piacenza, Italy on behalf of the 6 th Joint Task Force 2 3 Guidelines still based upon the principles of
More informationThe local healthcare system: Focusing on health
The local healthcare system: Focusing on health Sian Griffiths Professor of Public Health Director of the School of Public Health Chairman, Department of Community and Family Medicine The Chinese University
More information(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects
Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationUnderstanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s
Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s Ho Chi Minh City, Vietnam August 7, 2014 JBS 2 Risk Guidelines (2005) Based
More informationYuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China
What Can We Learn from the Observational Studies and Clinical Trials of Prehypertension? Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China At ARIC visit 4
More informationSecondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION
Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION Dr Kornelia Kotseva National Heart & Lung Insitute Imperial College London, UK on behalf of all investigators participating
More informationCVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic
CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationKnow Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up
Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up... Study Population: 340... Total Population: 500... Time Window of Baseline: 09/01/13 to 12/20/13... Time Window of Follow-up:
More informationASSeSSing the risk of fatal cardiovascular disease
ASSeSSing the risk of fatal cardiovascular disease «Systematic Cerebrovascular and coronary Risk Evaluation» think total vascular risk Assess the risk Set the targets Act to get to goal revised; aupril
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationAppendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular
More informationEuroPrevent 2010 Fatal versus total events in risk assessment models
EuroPrevent 2010 Fatal versus total events in risk assessment models Pekka Jousilahti, MD, PhD,Research Professor National Institute for Health and Welfare, Finland Risk assessment models Estimates the
More informationIs there a mechanism of interaction between hypertension and dyslipidaemia?
Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational
More informationFigure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution
Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution of A: total cholesterol (TC); B: low-density lipoprotein
More informationShould we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand
Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand Presentation outline Strengths & weaknesses of short-term risk approach Strengths &
More informationModelling Reduction of Coronary Heart Disease Risk among people with Diabetes
Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes Katherine Baldock Catherine Chittleborough Patrick Phillips Anne Taylor August 2007 Acknowledgements This project was made
More informationCheshire & Merseyside Cardiovascular Programme
Cheshire & Merseyside Cardiovascular Programme CVD Prevention and lipids: Are we doing enough? POP-UP UNIVERSITY SESSION Date: Thursday 6 September - Time: 10:45-11:45 Dr Scott W Murray Consultant Cardiologist
More informationAndrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University
CARDIOVASCULAR RISK FACTORS ORIGINAL ARTICLE Do We Correctly Assess the Risk of Cardiovascular Disease? Characteristics of Risk Factors for Cardiovascular Disease Depending on the Sex and Age of Patients
More informationEpidemiologic Measure of Association
Measures of Disease Occurrence: Epidemiologic Measure of Association Basic Concepts Confidence Interval for population characteristic: Disease Exposure Present Absent Total Yes A B N 1 = A+B No C D N 2
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More informationPhysical health assessment and monitoring in long-term mental health care
Physical health assessment and monitoring in long-term mental health care Dr Alan Farmer Consultant Psychiatrist Worcestershire Mental Health Partnership NHS Trust A brief questionnaire Current thoughts,
More informationMPharmProgramme. Hypertension (HTN)
MPharmProgramme Hypertension (HTN) Slide 1 of 30 Overview Definition Prevalence Type Causes Diagnosis Management Patients perspective Slide 2 of 30 Definition It is not a disease! So what is it? What two
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationVolume 2; Number 11 July 2008
Volume 2; Number 11 July 2008 CONTENTS Page 1 NICE Clinical Guideline 67: Lipid Modification (May 2008) Page 7 NICE Technology Appraisal 132: Ezetimibe for the treatment of primary (heterozygous familial
More informationABSTRACT: 9 DOES SOY CONSUMPTION HAVE AN EFFECT ON HYPERTENSION IN LOW-INCOME RURAL SOUTH AFRICAN WOMEN?
ABSTRACT: 9 DOES SOY CONSUMPTION HAVE AN EFFECT ON HYPERTENSION IN LOW-INCOME RURAL SOUTH AFRICAN WOMEN? W.H. OLDEWAGE-THERON & A.A. EGAL Centre of Sustainable Livelihoods, Vaal University of Technology,
More informationGetting serious about preventing cardiovascular disease
Getting serious about preventing cardiovascular disease Southwark s Experience Professor Kevin Fenton Director of Health and Wellbeing, London Borough of Southwark February 2018 Twitter: @ProfKevinFenton
More informationMississippi Stroke Systems of Care
Stroke Initiatives Mississippi State Department of Health Cassandra Dove, Chronic Disease Bureau 19 th Annual Stroke Belt Consortium March 1, 2014 Mississippi Stroke Systems of Care Heart Disease and Stroke
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationPrevenzione cardiovascolare e cambiamento degli stili di vita. Gian Franco Gensini
Prevenzione cardiovascolare e cambiamento degli stili di vita Gian Franco Gensini Main causes of death worldwide at all ages (year:: 2005) 17.5 milion Preventing Chronic Diseases A vital investiment. WHO
More informationPopulation models of health impact of combination polypharmacy
Population models of health impact of combination polypharmacy Global Summit on Combination Polypharmacy for CVD, 25 th September 2012 Dr Mark Huffman Northwestern University, Chicago Charity No: 1110067
More informationRisk Factors for NCDs
Risk Factors for NCDs Objectives: Define selected risk factors such as; tobacco use, diet, nutrition, physical activity, obesity, and overweight Present the epidemiology and significance of the risk factors
More informationWhy are NICE guidelines and standards important and relevant to us?
Why are NICE guidelines and standards important and relevant to us? Dr Liz England GP, Laurie Pike health centre RCGP Mental Health Clinical and Commissioning Lead SWB CCG Mental Health Lead NIHR Clinical
More informationHeart Age and Cardiovascular Risk
Heart Age and Cardiovascular Risk Mark Cobain Unilever R+D Colworth Science Park Sharnbrook Bedfordshire Europrevent, Geneva April 16 2011 Conflict of Interest Statement Employment by Unilever PLC A producer
More informationAbsolute cardiovascular disease risk management
Quick reference guide for health professionals Absolute cardiovascular disease risk management This quick reference guide is for use by health professionals for primary prevention of cardiovascular disease
More informationTable S1. Characteristics associated with frequency of nut consumption (full entire sample; Nn=4,416).
Table S1. Characteristics associated with frequency of nut (full entire sample; Nn=4,416). Daily nut Nn= 212 Weekly nut Nn= 487 Monthly nut Nn= 1,276 Infrequent or never nut Nn= 2,441 Sex; n (%) men 52
More informationCorporate Health Screening
Corporate Health Screening What should I look out for? Presented by: Dr Wee Wei Keong Director Health for Life Programme WHAT IS HEALTH SCREENING? Tests/procedures carried out to detect a condition/disease
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationHypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital
Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationDiabetes, Diet and SMI: How can we make a difference?
Diabetes, Diet and SMI: How can we make a difference? Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Relative
More informationPreventing Cardiovascular Disease Stroke Primary Prevention Guidelines. John Potter Professor Ageing & Stroke Medicine University of East Anglia
Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines John Potter Professor Ageing & Stroke Medicine University of East Anglia Preventing Cardiovascular Disease Stroke Primary Prevention
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationSecondary analyses of HSE data and linked health outcomes - an overview of work in progress. UCL (University College London)
Secondary analyses of HSE data and linked health outcomes - an overview of work in progress Dr Jennifer Mindell, UCL (University College London) Linked HSE mortality data (2008) In 2008, some mortality
More informationRandomized Design of ALLHAT BP Trial
Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* *Wright JT, Dunn JK, Cutler JA et al. JAMA 2005:293:1595-1608. 42,418 High-risk hypertensive
More informationWhat s new in cardiovascular disease risk assessment and management for primary care clinicians
Cardiovascular system What s new in cardiovascular disease risk assessment and management for primary care clinicians The recently released 2018 Cardiovascular Disease Risk Assessment and Management for
More informationIdentification of subjects at high risk for cardiovascular disease
Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Identification of subjects at high risk for cardiovascular disease Lars Rydén Karolinska Institutet
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationShiftwork and cardiometabolic outcomes. Dr Anil Adisesh
Shiftwork and cardiometabolic outcomes Dr Anil Adisesh 1 FACULTY/PRESENTER DISCLOSURE Faculty: Dr Anil Adisesh Relationships with commercial interests: - None 2 Aims 1) Participants will be able to describe
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationSerum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic
Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationHospital Authority Convention 2010 Presented by : Dr Cheng Ming Kin Medical Officer,Department of Medicine Tseung Kwan O Hospital
Hospital Authority Convention 2010 Prevalence of Cardiovascular Risk Factors, the Metabolic Syndrome and the 10-year risk for Coronary Heart Disease in the Staff of Tseung Kwan O Hospital Presented by
More informationGuidelines for Integrated Management of. Cardiovascular Diseases and Diabetes. in Clinics and Ri-hospitals
Guidelines for Integrated Management of Cardiovascular Diseases and Diabetes in Clinics and Ri-hospitals Ministry of Public Health DPR Korea January 2013 Rationale ncommunicable diseases such as cardiovascular
More informationNHS Health Check Training for Healthy Living Centre Staff and Colleagues. June 2015 Amanda Chappell
NHS Health Check Training for Healthy Living Centre Staff and Colleagues. June 2015 Amanda Chappell Aim of the session 1. Increase your understanding of the cardiovascular system 2. Describe the most common
More informationNHS Health Check Training for Healthy Living Centre Staff and Colleagues. June 2015 Amanda Chappell
NHS Health Check Training for Healthy Living Centre Staff and Colleagues. June 2015 Amanda Chappell Aim of the session 1. Understanding of the cardiovascular system 2. Describe the most common types of
More informationSIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence
SIGN 149 Risk estimation and the prevention of cardiovascular disease Quick Reference Guide July 2017 Evidence ESTIMATING CARDIOVASCULAR RISK R Individuals with the following risk factors should be considered
More informationCoronary Heart Disease in Women Go Red for Women
Coronary Heart Disease in Women Go Red for Women Dr Fiona Stewart Green Lane Cardiovascular Service and National Women s Health Auckland City Hospital Auckland Heart Group Women are Different from Men
More informationDr Anne King dc life dclife.co.uk
The Vampire Strikes Back Dr Anne King dc life dclife.co.uk Overview Clinical -v- Underwriting Blood physiology The blood sample Screening for the 3 main killers The top 3 useful blood tests The future
More informationCYNLLUN CODI CALON/UPLIFTING HEART PROJECT
CYNLLUN CODI CALON/UPLIFTING HEART PROJECT BACKGROUND OF PROJECT Joint initiative between psychiatric services and Gwynedd local health board, funded by WAG Inequalities in Health fund. Covering the county
More informationDiscussion points. The cardiometabolic connection. Cardiometabolic Risk Management in the Primary Care Setting
Session #5 Cardiometabolic Risk Management in the Primary Care Setting Sonja Reichert, MD MSc FCFP FACPM Betty Harvey, RNEC BScN MScN Amanda Mikalachki, RN BScN CDE S Discussion points Whom should we be
More informationUniversity of Padova, Padua, Italy, and HARVEST Study Group, Italy
University of Padova, Padua, Italy, and HARVEST Study Group, Italy ISOLATED SYSTOLIC HYPERTENSION IN THE YOUNG DOES NOT IMPLY AN INCREASED RISK OF FUTURE HYPERTENSION NEEDING TREATMENT Mos L, Saladini
More informationType 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.
Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to
More informationMetabolic Syndrome and Workplace Outcome
Metabolic Syndrome and Workplace Outcome Maine Worksite Wellness Initiative June 15, 2010 Alyssa B. Schultz Dee W. Edington Current Definition* of Metabolic Syndrome At least 3 of the following: Waist
More informationMetabolic Syndrome: A Preventable & Treatable Cluster of Conditions
Metabolic Syndrome: A Preventable & Treatable Cluster of Conditions April D. McNeill MD Candidate 2016, Southern Illinois University, School of Medicine GE-NMF Primary Care Leadership Program, July 2013
More informationCommunity Based Diabetes Prevention
Community Based Diabetes Prevention Melanie Davies Professor of Diabetes Medicine Outline NIHR Programme Grant proposal and update to progress The Vascular Check programme HbA1c debate Algorithm to detect
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationDyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III
More informationPhysical Health Checks
Improving the Quality of Physical Health Checks Kate Dale, Mental/Physical Health Project Lead BDCT Kate Beedle, Data Quality Specialist, West & South Yorkshire & Bassetlaw Commissioning Support Unit NB
More information22. Cardiovascular disease
22. Cardiovascular disease What is cardiovascular disease (CVD)? What conditions does the term CVD include? What is the aetiology of CVD? What are the risk factors for CVD? How do you assess the absolute
More informationBiases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of
More informationRisk Factors for Heart Disease
Risk Factors for Heart Disease Risk Factors we cannot change (Age, Gender, Family History) Risk Factors we can change (modifiable) Smoking Blood pressure Cholesterol Diabetes Inactivity Overweight Stress
More informationRick Fox M.A Health and Wellness Specialist
Metabolic Diseases Rick Fox M.A Health and Wellness Specialist Metabolic Diseases Metabolism is the process your body uses to get or make energy from the food you eat. Food is made up of proteins, carbohydrates
More informationSocioeconomic status and the 25x25 risk factors as determinants of premature mortality: a multicohort study of 1.7 million men and women
Socioeconomic status and the 25x25 risk factors as determinants of premature mortality: a multicohort study of 1.7 million men and women (Lancet. 2017 Mar 25;389(10075):1229-1237) 1 Silvia STRINGHINI Senior
More informationSupplemental Table 1. Study design and participant characteristics.
Supplemental Table 1. Study design and participant characteristics. Study ID Study Design; Total No. of Participants Mean age at Parity Participant Selection Criteria Country; Year (PE/no PE) Index Pregnancy
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationTable of Contents. Early Identification Chart Biometric Screening Comprehensive Cardiovascular Disease Risk Assessment...
Public Safety Table of Contents Early Identification Chart... 1 Biometric Screening... 2 Comprehensive Cardiovascular Disease Risk Assessment.... 2 Recommended after Comprehensive Cardiovascular Disease
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationCoronary heart disease and stroke
4 Coronary heart disease and stroke Overview of cardiovascular disease Cardiovascular disease (CVD), also called circulatory disease, describes a group of diseases which are caused by blockage or rupture
More informationUnderstanding the metabolic syndrome
Understanding the metabolic syndrome Understanding the metabolic system Metabolic syndrome is the clustering together of a number of risk factors for heart disease, stroke and diabetes. Having one of these
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationTo reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees.
E Nancy A. Haller, MPH, CHES, Manager, State Wellness Program M PLOYEES To reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees. To suspend or decrease the rising costs
More informationPREVER STUDY. What we learned with the PREVER-PREVENTION Trial? Dr. Sandra C. Fuchs. Professor at Universidade Federal of Rio Grande do Sul, Brazil
11 PREVER STUDY What we learned with the PREVER-PREVENTION Trial? Dr. Sandra C. Fuchs Professor at Universidade Federal of Rio Grande do Sul, Brazil Financial Support: PREVER investigators: Sandra C. FUCHS,
More informationCONTRIBUTING FACTORS FOR STROKE:
CONTRIBUTING FACTORS FOR STROKE: HYPERTENSION AND HYPERCHOLESTEROLEMIA Melissa R. Stephens, MD, FAAFP Associate Professor of Clinical Sciences William Carey University College of Osteopathic Medicine LEARNING
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:
More informationStroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital
Stroke secondary prevention Gill Cluckie Stroke Nurse Consultant St. George s Hospital Stroke recurrence The risk of recurrent stroke is greatest after first stroke 2 3% of survivors of a first stroke
More information